Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
PONIARD PHARMACEUTICALS, INC. (PARD)
|
Add to portfolio |
|
|
|
| Price: |
$0.00
| | Metrics |
| OS: |
60.0
|
M
| |
-266
|
% ROE
|
| Market cap: |
|
| |
-210
|
% ROIC
|
|
Net cash:
|
|
| |
|
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($14.3)
|
M
| |
|
|
|
EBIT
|
($15.5)
|
M
| |
|
|
| EPS |
($0.30)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 |
| Revenues | 8.0 | 25.7 | 33.7 | 22.4 | 13.4 | 10.2 | 14.3 | 20.1 |
| Revenue growth | -69.0% | -23.7% | 50.7% | 67.6% | 30.8% | -28.8% | -28.7% | -36.9% |
| Cost of goods sold | 18.8 | 17.2 | 33.7 | 22.4 | 13.4 | 10.2 | 13.3 | 9.6 |
| Gross profit | -10.8 | 8.5 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 10.5 |
| Gross margin | -135.3% | 33.0% | 0.0% | 0.0% | 0.0% | 0.1% | 7.1% | 52.3% |
| General and administrative | 17.1 | 14.7 | 15.4 | 13.1 | 7.5 | 5.9 | 7.2 | 6.3 |
| EBIT | -26.3 | -40.4 | -49.2 | -35.4 | -20.8 | -16.0 | -19.5 | -4.7 |
| EBIT margin | -330.2% | -157.1% | -145.7% | -158.0% | -156.0% | -156.4% | -135.8% | -23.3% |
| Pre-tax income | -30.1 | -45.7 | -48.6 | -32.8 | -23.3 | -21.0 | -19.4 | -5.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -30.8 | -46.2 | -49.1 | -33.3 | -23.8 | -21.5 | -19.9 | -7.5 |
| Net margin | -386.0% | -179.6% | -145.5% | -148.7% | -178.2% | -210.5% | -138.5% | -37.4% |
| |
| Diluted EPS | ($0.66) | ($1.31) | ($1.41) | ($1.08) | ($1.37) | ($3.83) | ($3.96) | ($0.28) |
| Shares outstanding (diluted) | 46.9 | 35.3 | 34.7 | 30.8 | 17.4 | 5.6 | 5.0 | 27.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|